{
  "id": "5e319617fbd6abf43b000049",
  "type": "factoid",
  "question": "Which clotting factor is in the Andexxa?",
  "ideal_answer": "Andexxa(r) is a first-in-class recombinant modified factor Xa protein. It is available to reverse life-threatening or uncontrolled bleeding with the factor Xa inhibitors apixaban and rivaroxaban.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30013295",
    "http://www.ncbi.nlm.nih.gov/pubmed/30362966",
    "http://www.ncbi.nlm.nih.gov/pubmed/30053385",
    "http://www.ncbi.nlm.nih.gov/pubmed/29926311",
    "http://www.ncbi.nlm.nih.gov/pubmed/30459509"
  ],
  "snippets": [
    {
      "text": "Intravenous andexanet alfa [coagulation factor Xa (recombinant), inactivated-zhzo; Andexxa\u00ae] is a first-in-class recombinant modified factor Xa protein that has been developed by Portola Pharmaceuticals as a universal antidote to reverse anticoagulant effects of direct or indirect factor Xa inhibitors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29926311",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fostamatinib (Tavalisse) for thrombocytopenia in adults with chronic immune thrombocytopenia; coagulation factor Xa (recombinant), inactivated-zhzo (Andexxa) for the reversal of anticoagulation; epoetin alfa-epbx (Retacrit), a biosimilar for the treatment of anemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30013295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30053385",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Andexanet alfa was approved in May 2018, under the brand name ANDEXXA, for the reversal of 2 of FXa inhibitors, apixaban and rivaroxaban, when life-threatening or uncontrolled bleeding occurs. This accelerated approval was based on change in anti-FXa activity from baseline that indicated a reversal of the anticoagulant effect.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30053385",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet Alfa for Reversing Factor Xa Inhibition.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30362966",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Andexanet alfa (Andexxa\u00ae, Portola Pharmaceuticals, San Francisco, CA) is a modified form of factor Xa that acts as a decoy binding entity for DOACs, thereby allowing endogenous factor Xa to perform its normal clotting functions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30362966",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa (Andexxa\u00ae), a first-in-class recombinant modified factor Xa protein, is currently the only specific agent available to reverse life-threatening or uncontrolled bleeding with the factor Xa inhibitors apixaban and rivaroxaban. Andexanet alfa acts as a decoy and competes with endogenous factor Xa to bind factor Xa inhibitors, thereby reversing the anticoagulant effects of factor Xa inhibitors, and restoring the activity of endogenous factor Xa. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30459509",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa (Andexxa, Portola Pharmaceuticals, San Francisco, CA) is a modified form of factor Xa that acts as a decoy binding entity for DOACs, thereby allowing endogenous factor Xa to perform its normal clotting functions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30362966",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa (Andexxa __sup__ \u00ae __end_sup__ ), a first-in-class recombinant modified factor Xa protein, is currently the only specific agent available to reverse life-threatening or uncontrolled bleeding with the factor Xa inhibitors apixaban and rivaroxaban.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30459509",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Intravenous andexanet alfa [coagulation factor Xa (recombinant), inactivated-zhzo; Andexxa __sup__ \u00ae __end_sup__ ] is a first-in-class recombinant modified factor Xa protein that has been developed by Portola Pharmaceuticals as a universal antidote to reverse anticoagulant effects of direct or indirect factor Xa inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29926311",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa was approved in May 2018, under the brand name ANDEXXA, for the reversal of 2 of FXa inhibitors, apixaban and rivaroxaban, when life-threatening or uncontrolled bleeding occurs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30053385",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa (Andexxa \u00ae ), a first-in-class recombinant modified factor Xa protein, is currently the only specific agent available to reverse life-threatening or uncontrolled bleeding with the factor Xa inhibitors apixaban and rivaroxaban.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30459509",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa (Andexxa, Portola Pharmaceuticals, San Francisco, CA) is a modified form of factor Xa that acts as a decoy binding entity for DOACs, thereby allowing endogenous factor Xa to perform its normal clotting functions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30362966",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Andexanet alfa was approved in May 2018, under the brand name ANDEXXA, for the reversal of 2 of FXa inhibitors, apixaban and rivaroxaban, when life-threatening or uncontrolled bleeding occurs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30053385",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Intravenous andexanet alfa [coagulation factor Xa (recombinant), inactivated-zhzo; Andexxa\u00ae] is a first-in-class recombinant modified factor Xa protein that has been developed by Portola Pharmaceuticals as a universal antidote to reverse anticoagulant effects of direct or indirect factor Xa inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29926311",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fostamatinib (Tavalisse) for thrombocytopenia in adults with chronic immune thrombocytopenia; coagulation factor Xa (recombinant), inactivated-zhzo (Andexxa) for the reversal of anticoagulation; epoetin alfa-epbx (Retacrit), a biosimilar for the treatment of anemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30013295",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Xa"
}